Press Enter to search · Esc to close
Semaglutide and liraglutide are quietly migrating from diabetes clinics into stem-cell labs and rare-disease wards — even as a social-media-driven shortage exposes the cost of off-label demand.
A new meta-analysis confirms GLP-1 drugs protect the heart and kidneys. Real-world data suggests pairing them with SGLT2 inhibitors may compound the benefit — with caveats worth understanding.
A new wave of population-level research is moving the link between chair-time and cancer from slogan to statistics — and reframing movement as a quiet prevention lever for desk-bound lives.
A real-world analysis tied to the dulaglutide shortage put concrete numbers on what happens to blood sugar in the three months after stopping. The picture is sobering — and worth bringing to your doctor.
The blockbuster weight-loss drug is being studied for far more than the scale. Here's what the newest research actually shows — and where the evidence still thins out.
A new pooled analysis of randomized trials isolates the non-diabetic obesity population — the use case driving most consumer demand — and quantifies what the dual GIP/GLP-1 agonist actually does, and what it costs.
Weekly semaglutide rewrote metabolic medicine. The pipeline behind it — a small-molecule pill, a twin-receptor agonist, and an injectable depot that lasts weeks — is now coming into focus.
Pooled real-world data on oral semaglutide, a fresh meta-analysis on combining GLP-1s with SGLT2 inhibitors, and dietitians' candid notes on what makes these protocols stick.